StockData
LIPOOTCPharmaceutical PreparationsFiscal year ends December 31

LIPELLA PHARMACEUTICALS INC.

Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$2.27K
P/E (TTM)
–
Dividend yield
–

About Lipella Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies by reformulating existing generic active pharmaceutical ingredients. The company utilizes a proprietary metastable liposome drug delivery platform designed for local drug application to body cavities lined with endothelial and mucosal surfaces. Its product pipeline includes LP-10 for the treatment of hemorrhagic cystitis, LP-310 for oral lichen planus, LP-410 for oral graft-versus-host disease, and LP-50 for non-muscle invasive bladder cancer. These candidates target patients suffering from severe inflammatory mucosal conditions and treatment-related complications.

The company operates an in-house manufacturing pilot plant to support the development and production of its product candidates. It does not commercialize products or maintain retail stores. Lipella Pharmaceuticals maintains its principal executive offices and headquarters in Pittsburgh, Pennsylvania.

Summary of the business section of Lipella Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
LIPELLA PHARMACEUTICALS INC.
Founded
2005
Headquarters
Pittsburgh, PA
Address
400 N Lexington St, Ste Ll103 15208
Phone
(412) 901-0315
Employees
5, Dec 31, 2024
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Urish Popeck & Co., LLC, Pittsburgh, PA

Stock & identifiers

Ticker
LIPO
Exchange
OTC
IPO date
Dec 21, 2022
Shares outstanding
5M, Nov 13, 2025
Public float
$2.62M, Jun 30, 2024
Filer category
<br>Emerging growth company
Stock splits
1-for-8 reverse, Nov 14, 2024; 1-for-8 reverse, Nov 8, 2024
SEC CIK
1347242
CUSIP
53630L209
ISIN
US53630L2097
LEI
549300NLVVVRGBF0WG69
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jonathan H. KaufmanSee remarks below., Director898,849

Employees

Headcount reported in annual reports

“As of March 26, 2025, we had five full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 15, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Mar 31, 2026BankruptcyBankruptcy or receivership (8-K Item 1.03)
Oct 6, 2025DelistingNotice of delisting from exchange (Form 25)
Jun 20, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 13, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 18, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 28, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 21, 2022IPOInitial public offering priced (424B4 prospectus)
Dec 19, 2022ListingRegistration of securities on an exchange (Form 8-A)